1. 98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE). (April 2019) Authors: Merrill, Joan T; June, Joshua; Koumpouras, Fotios; Machua, Wambui; Khan, Mohammed Faisal; Askanase, Anca D; Sheikh, Saira Z; Khosroshahi, Arezou; Foster, Paul; Zack, Debra J Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0176 PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). (June 2019) Authors: Merrill, Joan; June, Joshua; Koumpouras, Fotios; Machua, Wambui; Khan, Mohammad Faisal; Askanase, Anca; Khosroshahi, Arezou; Sheikh, Saira; James, Judith A.; Guthridge, Joel; Rathi, Gaurav; Burington, Bart; Foster, Paul; Zack, Debra Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 761 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗